Systemic Inflammatory Response Syndrome Treatment Market size was over USD 13.63 billion in 2024 and is poised to exceed USD 29.43 billion by 2037, growing at over 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of systemic inflammatory response syndrome treatment is evaluated at USD 14.34 billion.
Increasing incidences of systemic inflammatory response syndrome disease due to lifestyle changes, raising awareness about the disease, and the availability of treatments is expected to fuel this market's progress. The growth of the market can also be attributed to the rising prevalence of SIRS disease amongst individuals on a global level.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.10% |
|
Base Year Market Size (2024) |
USD 13.63 billion |
|
Forecast Year Market Size (2037) |
USD 29.43 billion |
|
Regional Scope |
|
On the basis of indication type, the systemic inflammatory response syndrome treatment market is segmented into meningitis, urinary tract infection (UTI), pneumonia, hemorrhage, autoimmune diseases, and others. Out of which, revenue from the treatment of urinary tract infection holds the highest share as dehydration, high consumption of birth control pills, menopause, and frequent involvement in sexual activities are leading causes of UTI. Females are more prone to UTI as they have a shorter urethra than males as a result, which shortens the distance for bacteria to reach the bladder.
On the basis of end-users, the market is segmented into hospital & ambulatory surgical centers, specialty clinics, and others. Specialty clinics segment hold the highest share of the systemic inflammatory response syndrome treatment market as a considerable portion of the population with disease on a global level tend to choose healthcare facilities specializing in specific treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By End User |
|
Geographically, the systemic inflammatory response syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific industry is likely to dominate majority revenue share by 2037, owing to increasing awareness about the disease and the need to develop innovative inflammatory disease treatment solutions in the region.
In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue followed by Europe.
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?